Elevance Health, Inc. (ELV)
| Market Cap | 92.84B +32.5% |
| Revenue (ttm) | 201.83B +3.6% |
| Net Income | 5.14B -7.1% |
| EPS | 23.44 -3.9% |
| Shares Out | 216.06M |
| PE Ratio | 18.33 |
| Forward PE | 14.92 |
| Dividend | $6.88 (1.60%) |
| Ex-Dividend Date | Dec 4, 2026 |
| Volume | 779,120 |
| Open | 432.18 |
| Previous Close | 429.90 |
| Day's Range | 420.81 - 433.67 |
| 52-Week Range | 274.84 - 450.69 |
| Beta | 0.63 |
| Analysts | Buy |
| Price Target | 482.38 (+12.26%) |
| Earnings Date | Oct 21, 2026 |
About ELV
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, a... [Read more]
Financial Performance
In 2025, Elevance Health's revenue was $199.13 billion, an increase of 12.62% compared to the previous year's $176.81 billion. Earnings were $5.66 billion, a decrease of -5.32%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for ELV stock is "Buy." The 12-month stock price target is $482.38, which is an increase of 12.26% from the latest price.
News
AM Best Assigns Indicative Issue Credit Ratings to Elevance Health, Inc.'s New Shelf Registration
OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has assigned indicative Long-Term Issue Credit Ratings of “bbb+” (Good) to senior unsecured issues, “bbb” (Good) to subordinated issues and “bbb-” ...
Elevance Health Transcript: UBS Global Healthcare Conference
Priorities include restoring margins, expanding Carelon capabilities and using data and AI to improve efficiency. The outlook targets at least 12% adjusted EPS growth in 2027, with Medicaid recovery, Medicare Advantage improvement and broader organic growth contributing.
Elevance to reaffirm FY26 adjusted EPS view at least $29.00, consensus $29.14
Officers of Elevance Health (ELV) expect to speak with investors and analysts this week. During these meetings, company officers will reaffirm the company’s shareholders’ earnings guidance for full ye...
Insurer Sues Autism-Therapy Provider Over $160 Million in Allegedly Misleading Claims
Elevance Health sued autism-therapy provider the Perfect Child, alleging that it paid the company $160 million due to misleading claims over the last five years.
Elevance Health files automatic mixed securities shelf
16:37 EDT Elevance Health (ELV) files automatic mixed securities shelf
Tennessee rate news positive for Elevance, UnitedHealth, says Evercore ISI
Evercore ISI notes that Tennessee has published Medicaid capitation rate schedules effective January 1, 2027, and estimates that rate increases imply about 5% repricing for both Elevance (ELV) and Uni...
Elevance Health price target raised to $495 from $465 at TD Cowen
TD Cowen raised the firm’s price target on Elevance Health (ELV) to $495 from $465 and keeps a Buy rating on the shares. The firm said they delivered a solid…
Elevance Health price target raised to $490 from $470 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on Elevance Health (ELV) to $490 from $470 and keeps an Outperform rating on the shares. The firm updated the company’s…
Elevance Health price target raised to $451 from $395 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Elevance Health (ELV) to $451 from $395 and keeps a Neutral rating on the shares. Elevance’s stronger Q3 results reflected improved underwriting…
Elevance Health price target raised to $500 from $475 at Truist
Truist raised the firm’s price target on Elevance Health (ELV) to $500 from $475 and keeps a Buy rating on the shares. The company’s Q3 revenue, earnings, and medical loss…
Elevance Health price target raised to $523 from $460 at UBS
UBS raised the firm’s price target on Elevance Health (ELV) to $523 from $460 and keeps a Buy rating on the shares.
Elevance Health price target raised to $455 from $424 at RBC Capital
RBC Capital raised the firm’s price target on Elevance Health (ELV) to $455 from $424 and keeps a Sector Perform rating on the shares. The company’s Q3 results beat expectations…
Elevance Health price target raised to $449 from $404 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on Elevance Health (ELV) to $449 from $404 and keeps an Equal Weight rating on the shares. Published first on…
Elevance Health price target raised to $500 from $480 at BofA
BofA analyst Kevin Fischbeck raised the firm’s price target on Elevance Health (ELV) to $500 from $480 and keeps a Buy rating on the shares. Elevance beat on Q3 adjusted…
Elevance Health price target raised to $485 from $460 at Guggenheim
Guggenheim analyst Jason Cassorla raised the firm’s price target on Elevance Health (ELV) to $485 from $460 and keeps a Buy rating on the shares, stating that Elevance reported strong…
Elevance Health price target raised to $406 from $393 at Baird
Baird raised the firm’s price target on Elevance Health (ELV) to $406 from $393 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results.
Elevance Health price target raised to $472 from $469 at Barclays
Barclays raised the firm’s price target on Elevance Health (ELV) to $472 from $469 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Elevance Health Earnings Call Transcript: Q3 2026
Q3 adjusted EPS of $6.99 beat outlook, lifting 2026 guidance to at least $29 and the earnings baseline to $26.75. Management targets at least 12% adjusted EPS growth in 2027, supported by health-benefit margin improvement, Carelon expansion and efficiency.
Elevance Health Earnings release: Q3 2026
Elevance Health released its Q3 2026 earnings on October 21, 2026, summarizing the period's financial results.
Elevance Health Slides: Q3 2026
Elevance Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 21, 2026.
Elevance Health Quarterly report: Q3 2026
Elevance Health has published its Q3 2026 quarterly earnings report on October 21, 2026.
Elevance Health appoints Jeff Park as president, Carelon
Elevance Health (ELV) announced the appointment of Jeff Park as President of Carelon, effective December 1, 2026. In this role, Park will lead Carelon through its next phase of growth,…
Elevance Health Names Jeff Park President of Carelon
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced the appointment of Jeff Park as President of Carelon, effective December 1, 2026. In this role, Park will lead Carelon throug...
Elevance Health Raises Yearly Outlook as Profit, Revenue Rise
For the third quarter, the health-insurance company reported a rise in net income to $1.34 billion, or $6.27 a share, compared with $1.19 billion, or $5.32 a share, a year earlier.
Elevance Health reports Q3 adjusted EPS $6.99, consensus $4.69
Reports Q3 revenue $50.4B, consensus $49.16B. “Elevance Health’s (ELV) third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the busine...